Department of Medicine, University of Padua, Padua, Italy.
Unit of Andrology and Reproductive Medicine, University Hospital of Padua, Padua, Italy.
Minerva Endocrinol (Torino). 2024 Jun;49(2):205-216. doi: 10.23736/S2724-6507.24.04171-X.
In transgender individuals assigned female at birth, testosterone therapy is employed for body masculinization. Guidelines recommend close monitoring for potential side effects of hormonal therapy, especially during the first year. Erythrocytosis is a common finding during testosterone therapy and has been associated with a potential risk of thrombotic and cardiovascular events. Currently, the hematologic effects of testosterone therapy are understudied, with existing data primarily derived from the cisgender male population. The aim of this study was to comprehensively examine the hematological changes induced by testosterone therapy in the transgender population.
A systematic search was conducted using the electronic database PubMed.
Thirty-six manuscripts were retrieved. After screening for original studies, 19 articles were included. Selected articles were published between 2005 and 2023.
In our systematic review, the prevalence of erythrocytosis varied from 0% to 29.3%, with severe erythrocytosis ranging from 0.5% to 2.3%. Testosterone therapy was associated with an increase in hemoglobin and hematocrit, particularly within the first year of therapy. Factors such as serum testosterone levels, along with the duration, doses, and formulation of testosterone therapy, were found to be associated with the development of erythrocytosis. Further research is crucial to provide specific recommendations for clinical practice.
在出生时被指定为女性的跨性别者中，会使用睾丸酮治疗来进行身体男性化。指南建议密切监测荷尔蒙治疗的潜在副作用，尤其是在第一年。红细胞增多症是睾丸酮治疗中的常见发现，并且与血栓形成和心血管事件的潜在风险相关。目前，睾丸酮治疗的血液学影响尚未得到充分研究，现有数据主要来自顺性别男性群体。本研究旨在全面检查睾丸酮治疗在跨性别者中引起的血液学变化。
使用电子数据库 PubMed 进行了系统检索。
检索到 36 篇手稿。经过对原始研究的筛选，纳入了 19 篇文章。入选的文章发表于 2005 年至 2023 年之间。
在我们的系统评价中，红细胞增多症的患病率从 0%到 29.3%不等，严重红细胞增多症的患病率从 0.5%到 2.3%不等。睾丸酮治疗与血红蛋白和血细胞比容的增加有关，尤其是在治疗的第一年。血清睾丸酮水平、治疗的持续时间、剂量和制剂等因素与红细胞增多症的发展有关。需要进一步的研究为临床实践提供具体的建议。
